125I Brachytherapy Ups Anastomotic Leakage in Rectal CA

This article originally appeared here.
Share this content:
<sup>125</sup>I Brachytherapy Ups Anastomotic Leakage in Rectal CA
125I Brachytherapy Ups Anastomotic Leakage in Rectal CA

MONDAY, June 6, 2016 (HealthDay News) -- For patients with rectal carcinoma, intraoperative iodine-125 seed implantation brachytherapy is associated with increased risk of anastomotic leakage (AL) and pelvic autonomic nerve dysfunction, according to a study published in the June issue of the Journal of Gastroenterology and Hepatology.

Ya-Jun Luo, from the Affiliated Hospital of North Sichuan Medical College in Nanchong, China, and colleagues conducted a pilot study involving patients with rectal cancer who received potentially curative resection of rectal carcinoma with 125I brachytherapy (17 patients) or radical resection of rectal carcinoma (34 patients). The authors compared the incidences of AL, fecal incontinence, urinary dysfunction, and sexual dysfunction.

The researchers found that 35.29 and 2.94 percent of patients in the 125I implant group and non-implant group, respectively, experienced AL (P = 0.006). There were significant between-group differences in the incidences of urinary dysfunction (P = 0.005) and fecal incontinence (P = 0.023). 125I brachytherapy was found to be an independent risk factor for AL and urinary dysfunction in multivariate analysis (odds ratios, 18.702 and 4.340, respectively). The recurrence rates were 5.56 and 9.09 percent in the 125I implant and non-implant groups, respectively, two years after surgery (P = 0.029).

"In general, this study suggests that intraoperative 125I brachytherapy is the preferred treatment for patients who have abdominoperineal resection with locally advanced rectal cancer, given that it is associated with an improved rate of local control and a superior overall compliance rate," the authors write. "125I brachytherapy is prudently used for selective patients who have low anterior resection with high risk of local recurrence, and complications and functional outcomes should be considered when counseling patients due to higher AL rates."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »